Dasatinib, a Kinase Inhibitor to Treat Chronic Myelogenous Leukemia
2010pp. 493–506
Citations Over Time
Abstract
This chapter contains sections titled: Introduction Discussion Clinical Findings and Summary References
Related Papers
- → Dasatinib or high‐dose imatinib for chronic‐phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily(2009)211 cited
- → The combination therapy of imatinib and dasatinib achieveslong-term molecular response in two imatinib-resistant anddasatinibintolerant patients with advanced chronic myeloid leukemia(2016)12 cited
- → Dasatinib is effective in imatinib-resistant CML(2007)5 cited
- → The combination therapy of imatinib and dasatinib achieves longterm molecular response in two imatinib-resistant and dasatinibintolerant patients with advanced chronic myeloid leukemia(2016)3 cited
- Dasatinib Achieves Higher Response Rate Than Imatinib in CML(2012)